Literature DB >> 27619810

Usage of 1,3-β-D-Glucan for Early Detection of Invasive Mycoses and Outcome Parameter in Immunocompromised Critically Ill Patients.

Tobias Lahmer1, Jürgen Held2, Sebastian Rasch3, Christopher Schnappauf3, Analena Beitz3, Roland M Schmid3, Wolfgang Huber3.   

Abstract

INTRODUCTION: Invasive fungal disease (IFD) remains a significant cause of morbidity and mortality in critically ill patients.
METHODS: Examination of 1,3-β-D-glucan (BDG) for IFD and as outcome parameter in immunocompromised critically ill patients with septic shock.
RESULTS: Thirty-two (69 %) out of 46 included patients had BDG beyond the cutoff of >80 pg/ml (mean 320 pg/ml). Twelve (37 %) had findings of Aspergillus spp. in BAL (mean BDG 413 pg/ml). EORTC/MSG guidelines classified these as probable invasive aspergillosis (IA)/IFD. Five (16 %) had candidaemia (mean BDG level 361 pg/ml). Sensitivity of 78 % (95 % CI 58-88 %) and specificity of 68 % (95 % CI 52-77 %) for IFD were found on the BDG Fungitell assay. In detail, a sensitivity of 73 % (95 % 58-84 %) and specificity of 83 % (95 % CI 68-93 %) for IA and a sensitivity of 77 % (CI 95 % 62-87 %) and specificity 53 % (95 % CI 37-73 %) for candidaemia were found. APACHE II, SOFA score and mortality rate were in the elevated BDG group significantly altered (26 vs. 21, p < 0.003; 15 vs. 13, p < 0.006; 72 vs. 50 %, p < 0.004).
CONCLUSION: 1,3-β-D-glucan assay is helpful for early detection of IFD; moreover, elevated BDG levels can be used as a predictor for outcome in immunocompromised critically ill patients as presented in our study.

Entities:  

Keywords:  1,3-β-D-glucan; Critically ill; Immunosuppression; Septic shock

Mesh:

Substances:

Year:  2016        PMID: 27619810     DOI: 10.1007/s11046-016-0061-0

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  27 in total

1.  Likelihood ratio: A powerful tool for incorporating the results of a diagnostic test into clinical decisionmaking.

Authors:  S R Hayden; M D Brown
Journal:  Ann Emerg Med       Date:  1999-05       Impact factor: 5.721

2.  Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1-->3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders.

Authors:  Masahito Kawazu; Yoshinobu Kanda; Yasuhito Nannya; Katsunori Aoki; Mineo Kurokawa; Shigeru Chiba; Toru Motokura; Hisamaru Hirai; Seishi Ogawa
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

3.  Difficulties in using 1,3-{beta}-D-glucan as the screening test for the early diagnosis of invasive fungal infections in patients with haematological malignancies--high frequency of false-positive results and their analysis.

Authors:  Zdenek Racil; Iva Kocmanova; Martina Lengerova; Barbora Weinbergerova; Lucie Buresova; Martina Toskova; Jana Winterova; Shira Timilsina; Isa Rodriguez; Jiri Mayer
Journal:  J Med Microbiol       Date:  2010-05-20       Impact factor: 2.472

4.  β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis.

Authors:  Drosos E Karageorgopoulos; Evridiki K Vouloumanou; Fotinie Ntziora; Argyris Michalopoulos; Petros I Rafailidis; Matthew E Falagas
Journal:  Clin Infect Dis       Date:  2011-03-15       Impact factor: 9.079

5.  Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry.

Authors:  William J Steinbach; Kieren A Marr; Elias J Anaissie; Nkechi Azie; Shun-Ping Quan; Herwig-Ulf Meier-Kriesche; Senu Apewokin; David L Horn
Journal:  J Infect       Date:  2012-08-13       Impact factor: 6.072

6.  Influence of various hemodialysis membranes on the plasma (1-->3)-beta-D-glucan level.

Authors:  H Kanda; K Kubo; K Hamasaki; Y Kanda; A Nakao; T Kitamura; T Fujita; K Yamamoto; T Mimura
Journal:  Kidney Int       Date:  2001-07       Impact factor: 10.612

7.  Experimental proof of contamination of blood components by (1-->3)-beta-D-glucan caused by filtration with cellulose filters in the manufacturing process.

Authors:  Koichi Nagasawa; Tatsuyuki Yano; Go Kitabayashi; Hiroaki Morimoto; Yuji Yamada; Atsushi Ohata; Makoto Usami; Takashi Horiuchi
Journal:  J Artif Organs       Date:  2003       Impact factor: 1.731

8.  Diagnostic performance of the (1-->3)-beta-D-glucan assay for invasive fungal disease.

Authors:  Sophia Koo; Julie M Bryar; John H Page; Lindsey R Baden; Francisco M Marty
Journal:  Clin Infect Dis       Date:  2009-12-01       Impact factor: 9.079

9.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

Review 10.  Role of (1-->3)-beta-D-glucan in the diagnosis of invasive aspergillosis.

Authors:  Francisco M Marty; Sophia Koo
Journal:  Med Mycol       Date:  2008-08-12       Impact factor: 4.076

View more
  3 in total

1.  A Retrospective Assessment of Four Antigen Assays for the Detection of Invasive Candidiasis Among High-Risk Hospitalized Patients.

Authors:  Barbara Hartl; Iris Zeller; Angelika Manhart; Brigitte Selitsch; Cornelia Lass-Flörl; Birgit Willinger
Journal:  Mycopathologia       Date:  2018-01-22       Impact factor: 2.574

2.  Clinical characteristics and risk factors for poor prognosis among HIV patients with Talaromyces marneffei bloodstream infection.

Authors:  Jianjun Sun; Weiwei Sun; Yang Tang; Renfang Zhang; Li Liu; Yinzhong Shen; Jiangrong Wang; Jun Chen; Tangkai Qi; Zhenyan Wang; Wei Song; Yixiao Lin; Shuibao Xu; Hongzhou Lu
Journal:  BMC Infect Dis       Date:  2021-06-01       Impact factor: 3.090

3.  (1→3)-β-D-glucan testing for the detection of invasive fungal infections in immunocompromised or critically ill people.

Authors:  Sandra K White; Robert L Schmidt; Brandon S Walker; Kimberly E Hanson
Journal:  Cochrane Database Syst Rev       Date:  2020-07-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.